Kevin C Maki - Böcker

Since the creation of the American Board of Clinical Lipidology, many clinicians have wanted an up-to-date, comprehensive reference on lipidology.

The second edition of this important book provides an up-to-date and comprehensive overview of clinical lipidology. Brand new chapters focus on recent advances in the field including novel biomarkers and the microbiome, genomics of cardiovascular risks, PCSK9 inhibitors, imaging technologies, and epidemiology of atherosclerotic cardiovascular disease.The book describes new guidelines, novel therapeutic agents, and changes in the understanding of specific lipoproteins and subclasses with regard to their relationships to cardiovascular disease risk. The second edition contains more than thirty chapters covering such topics as the history of lipidology, lipoprotein metabolism and vascular biology, disorders of lipid metabolism, lifestyle/dietary and pharmacologic management for dyslipidemia, the management of dyslipidemia in certain subgroups (e.g., women, children, older patients) and lipid testing, as well as an examination of other biomarkers and testing procedures related toatherosclerosis and cardiovascular disease. The second edition of Therapeutic Lipidology is an essential resource for physicians, medical students, residents, fellows, and allied health professionals in lipidology, cardiology, endocrinology, pharmacotherapy, and health promotion and disease prevention.

The second edition of this important book provides an up-to-date and comprehensive overview of clinical lipidology. Brand new chapters focus on recent advances in the field including novel biomarkers and the microbiome, genomics of cardiovascular risks, PCSK9 inhibitors, imaging technologies, and epidemiology of atherosclerotic cardiovascular disease.The book describes new guidelines, novel therapeutic agents, and changes in the understanding of specific lipoproteins and subclasses with regard to their relationships to cardiovascular disease risk. The second edition contains more than thirty chapters covering such topics as the history of lipidology, lipoprotein metabolism and vascular biology, disorders of lipid metabolism, lifestyle/dietary and pharmacologic management for dyslipidemia, the management of dyslipidemia in certain subgroups (e.g., women, children, older patients) and lipid testing, as well as an examination of other biomarkers and testing procedures related toatherosclerosis and cardiovascular disease. The second edition of Therapeutic Lipidology is an essential resource for physicians, medical students, residents, fellows, and allied health professionals in lipidology, cardiology, endocrinology, pharmacotherapy, and health promotion and disease prevention.

This book provides clinicians with the information needed to effectively interpret the literature from observational and interventional cardiovascular outcomes studies. The book begins by providing a historical context of cardiovascular epidemiology, followed by chapters addressing key concepts in the study of cardiovascular disease such as the types of cardiovascular outcomes studies, basic and evolving design and statistical considerations, current guidelines for reducing atherosclerotic cardiovascular disease risk, surrogate markers of cardiovascular disease, challenges in developing evidence-based recommendations for non-pharmacological interventions, an overview of the pharmaceutical development process, and a detailed discussion of the clinical evidence supporting several factors and their relationships with atherosclerotic cardiovascular disease (lipids, inflammation, hemostasis, heart rhythm, blood pressure, diabetes, obesity, and chronic kidney disease).  Cardiovascular Outcomes Research is a must-have resource for physicians and other clinicians, residents, fellows, and medical students in cardiology, endocrinology, primary care, and health promotion and disease prevention.